(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.17%
@ $6.00
Utstedt: 14 feb 2024 @ 20:22
Avkastning: -23.33%
Forrige signal: feb 14 - 19:08
Forrige signal:
Avkastning: -5.73 %
Live Chart Being Loaded With Signals
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa...
Stats | |
---|---|
Dagens volum | 2.68M |
Gjennomsnittsvolum | 592 980 |
Markedsverdi | 125.83M |
EPS | $0 ( 2024-04-03 ) |
Neste inntjeningsdato | ( $-0.470 ) 2024-05-09 |
Last Dividend | $3 706.25 ( 2000-03-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.820 |
ATR14 | $0.0150 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Seshadri Vishwas | Buy | 10 000 | Common Stock |
2024-04-26 | Charles Faith L. | Buy | 7 550 | Common Stock |
2024-04-25 | O'malley Brendan M. | Buy | 8 600 | Common stock |
2024-04-25 | Vazzano Joseph Walter | Buy | 5 608 | Common stock |
2024-03-15 | Vazzano Joseph Walter | Sell | 703 | Common stock |
INSIDER POWER |
---|
82.88 |
Last 95 transactions |
Buy: 4 778 989 | Sell: 610 127 |
Volum Korrelasjon
Abeona Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
NVDA | 0.94 |
COOL | 0.939 |
BOTZ | 0.938 |
OPRA | 0.935 |
SVAC | 0.932 |
AVGO | 0.924 |
ADVM | 0.923 |
SMCI | 0.923 |
DFH | 0.922 |
TQQQ | 0.921 |
10 Mest negative korrelasjoner | |
---|---|
AMRB | -0.953 |
LWAC | -0.916 |
SOPA | -0.913 |
ONCR | -0.909 |
PHCF | -0.907 |
SRAC | -0.9 |
PRDO | -0.89 |
QTEK | -0.888 |
AGFS | -0.887 |
SQQQ | -0.885 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Abeona Therapeutics Inc Korrelasjon - Valuta/Råvare
Abeona Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $3.50M |
Bruttogevinst: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2023 |
Omsetning: | $3.50M |
Bruttogevinst: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2022 |
Omsetning: | $1.41M |
Bruttogevinst: | $964 000 (68.18 %) |
EPS: | $-4.05 |
FY | 2021 |
Omsetning: | $3.00M |
Bruttogevinst: | $3.00M (100.00 %) |
EPS: | $-21.57 |
Financial Reports:
No articles found.
Abeona Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $3 706.25 | 2000-03-31 |
Last Dividend | $3 706.25 | 2000-03-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $3 706.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $3.00 | 0.03% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -15.48 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.847 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.34 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.10 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.103 | 1.500 | 4.98 | 7.47 | [0.2 - 2] |
debtRatioTTM | 0.0844 | -1.500 | 8.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -115.31 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.448 | 2.00 | -0.483 | -0.965 | [0 - 30] |
freeCashFlowPerShareTTM | -1.461 | 2.00 | -0.731 | -1.461 | [0 - 20] |
debtEquityRatioTTM | 0.364 | -1.500 | 8.54 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0863 | 1.000 | -1.895 | -1.895 | [0.2 - 0.8] |
operatingProfitMarginTTM | -13.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -6.85 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0547 | 0.800 | -2.97 | -2.38 | [0.5 - 2] |
Total Score | -2.42 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.17 | 1.000 | -0.320 | 0 | [1 - 100] |
returnOnEquityTTM | -3.34 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.461 | 2.00 | -0.487 | -1.461 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.448 | 2.00 | -0.483 | -0.965 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00365 | 1.500 | -3.31 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -10.57 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.72 |
Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.